HMN 2025: How New route into cells may make gene therapies safer

Scientists from the Centenary Institute and the University of Sydney have made a landmark discovery that might result in safer and simpler gene therapies for a variety of great genetic problems together with Duchenne muscular dystrophy, Pompe illness and hemophilia.

Published in Cell, the study identifies a beforehand unknown gateway into human cells, a receptor known as AAVR2, that gene remedy viruses use to ship therapeutic genes. This newly uncovered pathway may permit decrease doses of virus for use in therapy, serving to to cut back unwanted side effects and therapy prices, whereas enhancing affected person outcomes.

Gene therapies usually use modified viruses, generally known as adeno-associated viruses (AAVs), to ship wholesome genes into the physique. These therapies have the potential to be life-changing for sufferers, their households and caregivers. However, they steadily require excessive vector doses to realize therapeutic results which in some circumstances can set off extreme immune responses, result in critical issues, and even demise.

“We discovered that sure AAV varieties can use this newly recognized receptor, AAVR2, to enter cells, offering an alternative choice to the beforehand recognized entry route,” stated Dr. Bijay Dhungel, lead creator of the review and researcher on the Centenary Institute’s Center for Rare Diseases & Gene Therapy and the University of Sydney.

“This discovery uncovers a very new pathway for delivering genes into cells. Modulating this pathway can probably make gene therapies safer, cheaper and extra exact,” he stated.

Using superior genetic, biochemistry and molecular biology strategies, the researchers confirmed that AAVR2 performs a vital position in serving to a number of AAV varieties, together with these broadly utilized in sufferers, enter cells extra effectively.

“We not solely recognized this new receptor, AAVR2, but in addition found the way it binds to the viruses that ship the genes,” stated co-senior creator Dr. Charles (Chuck) Bailey, Head of the Center for Rare Diseases & Gene Therapy on the Centenary Institute and researcher on the University of Sydney.

“We then went a step additional and engineered a miniature model of the receptor and demonstrated that this considerably enhances how effectively the gene remedy is taken up in human cells and tissues. We consider this data will finally enhance the accessibility of gene therapies to sufferers.”

The researchers say the findings have vital implications for the way forward for gene remedy, providing new methods to tailor therapies, decrease required doses and probably keep away from immune-related issues which have restricted some present approaches.

The discovery additionally advances scientific understanding of how therapeutic viruses work together with human cells. This is important data for creating the next-generation of protected, efficient and precision-guided gene therapies.